HBD performed a feasibility study on the economics of growing Catharanthus roseus under controlled circumstances in greenhouses for the production of anti-cancer compounds such as the alkaloids vinblastine and vincristine.

Holland Biodiversity formed a consortium with three research institutes and one partner from industry to carry out a feasibility study, subsidized by Kennisalliantie Zuid-Holland, to identify compounds from waste materials of greenhouse-grown plants, such as for example waste bulb material from tuplis, with pharmaceutical, agrochemical or cosmetic applications. A positive conclusion from the feasibility study may lead to an extensive research and development program in this area.

Holland Biodiversity was granted an innovation voucher from Senter (now Agentschap NL). The voucher is used to conduct research aimed at increasing galanthamine levels in daffodils. Galanthamine is used as a medicine for Alzheimer's disease. The research is carried out in collaboration with three other companies.